FDA Approves LEVOCETIRIZINE DIHYDROCHLORIDE — Macleods Pharmaceuticals Limited
# FDA Approves Macleods Pharmaceuticals' Generic Levocetirizine Dihydrochloride Macleods Pharmaceuticals Limited received FDA approval for its generic levocetirizine dihydrochloride oral formulation (ANDA205564) on January 11, 2016, potentially expanding competition in the antihistamine market and offering patients a lower-cost alternative to brand-name allergy medications. The approval is expected to intensify pricing pressure in the over-the-counter and prescription antihistamine segment as generic manufacturers vie for market share.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day